SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2017 / Cilt: 42 - Sayı: 5

Serum levels of growth factors in patients with urinary bladder cancer

Mesane kanserli hastalarda serum büyüme faktörleri düzeyleri

Eylem Efe KOÇ
Mustafa Bilal TUNA
Şölen HİMMETOĞLU
Süleyman - Yildiz ATAUS -DİNCER
Pages
571–575
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Despite the lack of a significant association between sHER-2/neu level and pathological pT stage, sHER-2/neu may be a promising marker for UBC but IGF-1 and EGF have not such a potential

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Altered signalling of human epidermal growth factor receptor-2 (HER-2/neu), insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF) have been shown to play important role in tumor development and progression in various cancers.
📊
Key Findings & Data:Their serum levels may be reliable indicator for diagnosis and progression of cancer.Objective: To examine the serum levels of soluble HER-2/neu (sHER-2/neu), IGF1 and EGF in patients with urinary bladder cancer (UBC).Material and methods: Serum levels of sHER-2/neu, IGF1 and EGF were measured by enzyme-linked immune assay in newly diagnosed, untreated patients with UBC.Results: In the patient group, sHER-2/neu level was found to be increased, IGF1 level was found to be decreased in comparison to those in the control group.
💡
Conclusion & Impact:Despite the lack of a significant association between sHER-2/neu level and pathological pT stage, sHER-2/neu may be a promising marker for UBC but IGF-1 and EGF have not such a potential
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Altered signalling of human epidermal growth factor receptor-2 (HER-2/neu), insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF) have been shown to play important role in tumor development and progression in various cancers. Their serum levels may be reliable indicator for diagnosis and progression of cancer.Objective: To examine the serum levels of soluble HER-2/neu (sHER-2/neu), IGF1 and EGF in patients with urinary bladder cancer (UBC).Material and methods: Serum levels of sHER-2/neu, IGF1 and EGF were measured by enzyme-linked immune assay in newly diagnosed, untreated patients with UBC.Results: In the patient group, sHER-2/neu level was found to be increased, IGF1 level was found to be decreased in comparison to those in the control group. Although serum level of sHER-2/neu was lower in the patients with Ta stage than that in the patients with T1 and T2 stages, this difference was not at a statistically significant level.Conclusion: Serum level of sHER-2/neu is increased in patients with UBC. Despite the lack of a significant association between sHER-2/neu level and pathological pT stage, sHER-2/neu may be a promising marker for UBC but IGF-1 and EGF have not such a potential

Özet

Giriş: İnsan epidermal büyüme faktörü reseptörü (HER-2/neu), insülin benzeri büyüme faktörü 1 (IGF-1) ve epidermal büyüme faktörü (EGF) sinyalizasyonundaki değişikliklerin tümör oluşumu ve ilerlemesinde önemli rol oynadığı çeşitli kanserlerde gösterilmiştir. Bunların serumdaki düzeyleri kanserin tanı ve prognozunun belirlenmesinde anlamlı bir belirteç olabilir.Amaç: Mesane kanserli hastalarda serum çözünebilir HER-2/neu (sHER-2/neu), IGF1 ve EGF düzeylerinin belirlenmesi.Materyal ve metodlar: Yeni tanı konmuş, henüz tedavi almamış mesane kanserli hastalarda serum sHER-2/neu, IGF1 ve EGF düzeyleri enzim-bağlı immun yöntemlerle ölçüldü.Bulgular: Hasta grubunda kontrol grubuna kıyasla sHER-2/neu düzeyi artmış, IGF1 düzeyi azalmış olarak bulundu. Ta evreli hastalarda serum sHER-2/neu düzeyi T1 ve T2 evreli hastalardakine göre düşük olsa da, bu farklılık istatistiksel olarak anlamlı düzeyde değildi.Sonuç: Mesane kanserli hastalarda serum sHER-2/neu düzeyi artmıştır. sHER-2/neu düzeyi ile patolojik pT evresi arasında anlamlı bir ilişki olmasa da, sHER-2/neu mesane kanseri için umut verici bir belirteç olabilir fakat IGF-1 ve EGF böyle bir potansiyele sahip değildir

🔖

Cite This Article

KOÇ, E. E., TUNA, M. B., HİMMETOĞLU, Ş., -DİNCER, S. -. Y. A. (2022). Serum levels of growth factors in patients with urinary bladder cancer. Türk Biyokimya Dergisi, Cilt: 42 - Sayı: 5, 571–575. https://ajindex.com/articles/621006

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dal Moro F, Valotto C, Guttilla A, Zattoni F. Urinary markers in the everyday diagnosis of bladder cancer. Urologia 2013;80:265–75
  2. Urquidi V, Rosser CJ, Goodison S. Multiplex urinary tests for bladder cancer diagnosis. Eur Med J Urol 2013;1:70–3
  3. Bechmann T, Madsen JS, Brandslund I, Lund ED, Ormstrup T, J Erik Hugger, et al. Predicting brain metastases of breast cancer based on serum S100B and serum HER2. Oncol Lett 2013;6:1265–70
  4. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003;49:1579–98
  5. Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Kahlert S, et al. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clin Chim Acta 2014;430:86–91
  6. Siampanopoulou M, Galaktidou G, Dimasis N, GotzamaniPsarrakou A. Profiling serum HER-2/neu in prostate cancer. Hippokratia 2013;17:108–12
  7. Tsigris C, Karayiannakis AJ, Zbar A, Syrigos KN, Baibas N, Diamantis T, et al. Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. Cancer Lett 2002;184:215–22
  8. Tsigris C, Karayiannakis AJ, Syrigos KN, Zbar A, Diamantis T, Kalahanis N, et al. Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer. Anticancer Res 2002;22:3061–5
  9. Tambo M, Higashihara E, Terado Y, Nutahara K, Okegawa T. Comparison of serum HER2/neu with immunohistochemical HER2/ neu expression for the prediction of biochemical progression in metastatic prostate cancer. Int J Urol 2009;16:369–74
  10. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307–25
  11. Menczer J, Schreiber L, Czernobilsky B, Berger E, Golan A. Is Her-2/neu expressed in nonepithelial ovarian malignancies? Am J Obstet Gynecol 2007;196:79.e1–4
  12. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 2006;16:1897–902
  13. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER-2/ neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371–9
  14. Park DI, Kang MS, Oh SJ, Kim SJ, Cho YK, Sohn CI, et al. HER-2/ neu overexpression is an independent prognostic factor in colorectal cancer. Int